TABLE 1.

Published clinical trials targeting PD-1 pathway in cancer patients.

Cancer types	Sponsor/Company	Target	References
Melanoma	BMS	PD-1	38, 40, 42, 43, 44, 49, 51, 60
		PD-L1	39
	Merck	PD-1	41, 48
	Roche/Genentech	PD-L1	45, 61
Non small-cell lung cancer (NSCLC)	BMS	PD-1	40 49
		PD-L1	39
	Merck	PD-1	58, 59
	Roche/Genentech	PD-L1	45
	AstraZeneca/MedImmune	PD-L1	54, 57
Renal cell cancer (RCC)	BMS	PD-1	38, 40, 42, 46, 49
		PD-L1	39
	Roche/Genentech	PD-L1	45
Urothelial bladder cancer (UBC)	Merck	PD-1	56
	Roche/Genentech	PD-L1	47
Hodgkin’s lymphoma	BMS	PD-1	50
Head and neck cancer	Merck	PD-1	55
	Roche/Genentech	PD-L1	45, 53
	AstraZeneca/MedImmune	PD-L1	54
Triple negative breast cancer	Merck	PD-1	52
	Roche/Genentech	PD-L1	62

BMS, Bristol-Myers Squibb